Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Accelerate Diagnostics, Inc is a diagnostics & research business based in the US. Accelerate Diagnostics shares (AXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Accelerate Diagnostics employs 275 staff and has a trailing 12-month revenue of around USD$10.2 million.
Since the stock market crash in March caused by coronavirus, Accelerate Diagnostics's share price has had significant negative movement.
Its last market close was USD$8.71, which is 46.00% down on its pre-crash value of USD$16.13 and 92.27% up on the lowest point reached during the March crash when the shares fell as low as USD$4.53.
If you had bought USD$1,000 worth of Accelerate Diagnostics shares at the start of February 2020, those shares would have been worth USD$346.61 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$509.10.
|Latest market close||USD$8.71|
|52-week range||USD$4.53 - USD$19.11|
|50-day moving average||USD$11.0917|
|200-day moving average||USD$11.8807|
|Wall St. target price||USD$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.599|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||4.44%|
|1 month (2020-10-30)||-7.54%|
|3 months (2020-08-28)||-27.78%|
|6 months (2020-05-29)||4.31%|
|1 year (2019-11-29)||-41.70%|
|2 years (2018-11-29)||-37.61%|
|3 years (2017-11-29)||-68.89%|
|5 years (2015-11-27)||-49.45%|
|Revenue TTM||USD$10.2 million|
|Gross profit TTM||USD$4.4 million|
|Return on assets TTM||-31.71%|
|Return on equity TTM||-837.84%|
|Market capitalisation||USD$656 million|
TTM: trailing 12 months
There are currently 15.7 million Accelerate Diagnostics shares held short by investors – that's known as Accelerate Diagnostics's "short interest". This figure is 5.1% up from 14.9 million last month.
There are a few different ways that this level of interest in shorting Accelerate Diagnostics shares can be evaluated.
Accelerate Diagnostics's "short interest ratio" (SIR) is the quantity of Accelerate Diagnostics shares currently shorted divided by the average quantity of Accelerate Diagnostics shares traded daily (recently around 284158.6475707). Accelerate Diagnostics's SIR currently stands at 55.16. In other words for every 100,000 Accelerate Diagnostics shares traded daily on the market, roughly 55160 shares are currently held short.
However Accelerate Diagnostics's short interest can also be evaluated against the total number of Accelerate Diagnostics shares, or, against the total number of tradable Accelerate Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Accelerate Diagnostics's short interest could be expressed as 0.28% of the outstanding shares (for every 100,000 Accelerate Diagnostics shares in existence, roughly 280 shares are currently held short) or 0.4933% of the tradable shares (for every 100,000 tradable Accelerate Diagnostics shares, roughly 493 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Accelerate Diagnostics.
Find out more about how you can short Accelerate Diagnostics stock.
We're not expecting Accelerate Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, Accelerate Diagnostics's shares have ranged in value from as little as $4.53 up to $19.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Accelerate Diagnostics's is 2.5367. This would suggest that Accelerate Diagnostics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.